Publications
Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: Systematic review and meta-analysis
Citation
Solitano V, Vuyyuru SK, MacDonald JK, Zayadi A, Parker CE, Narula N, Peyrin-Biroulet L, Danese S, Feagan BG, Singh S, Ma C, Jairath V. Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: Systematic review and meta-analysis. J Crohns Colitis. 2023 Jun 15:jjad100. doi: 10.1093/ecco-jcc/jjad100. Epub ahead of print. PMID: 37317532.
Abstract
Background and aims: Oral small-molecule drugs (SMDs) are expanding the therapeutic landscape for inflammatory bowel disease (IBD). This systematic review and meta-analysis summarises the efficacy and safety of JAK inhibitor (JAKi) and sphingosine-1-phosphate (S1P) receptor modulator treatments for ulcerative colitis (UC) and Crohn’s disease (CD).
